Compare Otis Worldwide Corp (OTIS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Otis Worldwide Corp vs BIO-TECHNE Corp — how do they compare? Otis Worldwide Corp trades at $69.36 (market cap $26.67B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: Otis Worldwide Corp is far larger — about 2.4× BIO-TECHNE Corp's market cap, and Otis Worldwide Corp pays the higher dividend (2.51%). Which is the better fit depends on your goals.
| OTIS | TECH | |
|---|---|---|
Market Cap | $26.67B | $11.34B |
Sector | Industrials | Health |
52-Week High | $93.62 | $72.48 |
52-Week Low | $69.30 | $43.31 |
Enterprise Value | $34.70B | $11.36B |
Dividend Yield | 2.51% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Otis Worldwide (OTIS) trades at $70.06, down 1.61% on the day, amid a bearish technical signal and recent earnings misses. The stock shows a P/E of 18.01 and P/S of 1.83, with strong cash flow from operations of $1.60B in 2025 but a negative net cash flow of -$1.22B. Recent news includes a dividend declaration and new contracts in China, while technical indicators highlight support near $70 and an oversold RSI.
The outlook is mixed: analyst consensus is a Buy with a $92.50 price target, implying upside, but risks include high debt-to-asset ratio of 75.54% and margin pressure from labor costs. Service segment growth offers stability, yet weak new equipment demand and guidance cuts temper near-term optimism.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
